Saw Palmetto vs Beta-Sitosterol — BPH evidence, head-to-head

Updated 2026-05-12 · Reviewed by SupplementScore editors · No sponsorships

Saw palmetto is the BPH supplement everyone has heard of. Beta-sitosterol is the one with better trial data. The CAMUS trial in 2011 — the largest, longest, best-blinded saw palmetto trial — showed no benefit over placebo at standard or high doses, and three subsequent Cochrane reviews have aligned with that finding. Beta-sitosterol, a plant phytosterol, has a smaller but cleaner trial base showing genuine improvements in lower urinary tract symptoms (LUTS) and urinary flow. The popular choice and the evidence-based choice are not the same here.

Quick verdict

How they're supposed to work

Saw palmetto — the 5-α reductase hypothesis

Saw palmetto (Serenoa repens) extract was originally hypothesised to inhibit 5-α reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT), the androgen most implicated in prostate enlargement. In vitro and animal studies are supportive of weak 5-α reductase activity. The problem is that in humans at supplement doses, saw palmetto produces no clinically meaningful change in serum DHT, prostate-specific antigen (PSA), or prostate volume — endpoints that genuine 5-α reductase inhibitors (finasteride, dutasteride) move substantially. The mechanism doesn't deliver in vivo, and the clinical trial endpoints reflect that.

Beta-sitosterol — phytosterol with unclear but real signal

Beta-sitosterol is a plant phytosterol present in many seeds and oils, structurally similar to cholesterol. Its mechanism in BPH isn't fully characterised but appears to involve anti-inflammatory effects on prostate tissue and modulation of bladder contractility rather than direct hormone manipulation. The trial evidence base is smaller than saw palmetto's but more consistent — a 1999 Cochrane review (Wilt et al.) of 4 placebo-controlled RCTs (n=519) found significant improvements in IPSS, peak urinary flow rate, and residual urine volume. Effect sizes were modest but real.

What the trial data actually shows

Saw palmetto: the CAMUS trial (Barry 2011, n=369, 72 weeks) randomised men with moderate-to-severe BPH to saw palmetto extract at 320 mg/day, 640 mg/day, 960 mg/day, or placebo. No significant difference in AUASI (American Urological Association Symptom Index) at any dose vs placebo. The Cochrane 2012 review (Tacklind et al., 32 RCTs, n=5,666) found no significant benefit on symptom scores or urinary flow vs placebo. Multiple subsequent trials and meta-analyses have aligned. Permixon® (the most-tested specific extract) has shown some positive trials, but the pattern at scale is null.

Beta-sitosterol: the Wilt 1999 Cochrane review of 4 RCTs (n=519) showed significant improvement in IPSS (mean difference -4.9 points), peak flow (mean difference +3.91 mL/sec), and residual urine volume. The effect size on symptom scores is meaningful and comparable to alpha-blockers in some trials. The trials are older and smaller than the saw palmetto literature, but the signal is more consistent.

What they don't do — important for managing expectations

Neither shrinks the prostate. Neither reduces PSA. Neither has been shown to reduce progression to acute urinary retention or surgery. For men with significant obstruction, residual urine, or signs of bladder decompensation, neither is an adequate substitute for guideline-directed therapy (alpha-blockers, 5-α reductase inhibitors, or surgical intervention). Both are positioned as "mild-to-moderate symptom relief, NSAID-sparing-style adjuncts" — not disease-modifying therapy.

Dose, form, and timing

Beta-sitosterol: 60–130 mg/day in 2–3 divided doses with meals. The trial-tested products were standardised mixed phytosterol preparations dominated by beta-sitosterol. Generic phytosterol blends at the same beta-sitosterol content are reasonable; "raw" pumpkin seed extract is a related but less standardised intervention.

Saw palmetto (if used): 320 mg/day of standardised lipidosterolic extract (85–95% fatty acids and sterols), typically as Permixon® or equivalent. Take with food.

Safety

Both are generally well-tolerated. Saw palmetto's most consistent adverse effects are mild GI symptoms; rare reports of more serious effects (gynecomastia, pancreatitis, hepatic signals) are inconsistent. Theoretical antiplatelet effect — caution with anticoagulants. PSA: saw palmetto does not artificially lower PSA in the way finasteride does (which is clinically important — finasteride masks PSA elevation in prostate cancer screening), but this is worth confirming with the prescriber if there are screening considerations.

Beta-sitosterol: well-tolerated. Modest cholesterol-lowering as a side effect (typically beneficial). Theoretical caution in users with the rare genetic disorder sitosterolemia.

What the price difference buys you

Saw palmetto runs $10–25/month at standardised-extract doses. Beta-sitosterol runs $5–15/month at trial-cited doses. Combination "prostate" formulas often add zinc, pumpkin seed, lycopene, and stinging nettle — most of these have weaker evidence than beta-sitosterol alone, and bundle pricing dilutes per-ingredient dose.

What to skip

• Multi-ingredient "men's prostate" formulas at premium prices — typically under-dose every active component.
• Saw palmetto if you've trialled it at full dose for 12 weeks without symptom improvement — the evidence base predicts placebo-equivalent results.
• Any prostate supplement as a substitute for medical evaluation of new urinary symptoms in men over 50 — particularly rapid-onset symptoms, hematuria, or unusual prostate exam findings.

Who should pick each

Pick beta-sitosterol if: you have mild-to-moderate LUTS, you've consulted a clinician, you want an evidence-based first-line supplement adjunct, you accept that effects are modest.

Pick saw palmetto if: you've already tried beta-sitosterol without benefit and want to add saw palmetto as a second-line trial with full understanding that the larger trial base is null. Or if you and your clinician agree to trial it for 12 weeks and reassess against pre-defined symptom criteria.

What we'd actually buy

For BPH symptom adjunct: beta-sitosterol 130 mg/day in divided doses, $5–15/month. The cleaner evidence base in the supplement category.

For users seeking the "natural BPH supplement" they've heard of (saw palmetto): manage expectations against the trial data, set a 12-week trial period with a defined IPSS or AUASI reassessment, and discontinue if no symptom improvement.

Sources

• Barry MJ, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: the CAMUS randomized trial. JAMA. 2011;306(12):1344–1351. PMID: 21954478
• Tacklind J, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;12:CD001423. PMID: 23235581
• Wilt TJ, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001043. PMID: 10796740
• Berges RR, et al. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 2000;85(7):842–846. PMID: 10792163
• Klippel KF, et al. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol. 1997;80(3):427–432. PMID: 9313664
• MacDonald R, et al. Serenoa repens monotherapy for benign prostatic hyperplasia: an updated Cochrane systematic review. BJU Int. 2012;109(12):1756–1761. PMID: 22551330